Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTWS9E)

Drug Name
Apremilast Drug Info
Synonyms Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Approved [1]
Psoriatic arthritis FA21 Approved [2]
Cross-matching ID
PubChem CID
11561674
ChEBI ID
CHEBI:78540
CAS Number
CAS 608141-41-9
TTD Drug ID
DMTWS9E
VARIDT Drug ID
DR01264
INTEDE Drug ID
DR0124
ACDINA Drug ID
D00041

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Oxtriphylline DMLHSE3 Cough MD12 Approved [8]
Roflumilast DMPGHY8 Asthma CA23 Approved [9]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [10]
crisaborole DMNVKU6 Atopic dermatitis EA80 Approved [11]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [12]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [13]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [14]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [12]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [15]
IC-485 DMB1UYV Chronic obstructive pulmonary disease CA22 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [16]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [17]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [8]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [18]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [19]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [20]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [21]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [22]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [23]
GLR2007 DM7DWLY Glioblastoma of brain 2A00.00 Phase 1/2 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 6 (CDK6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [16]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [17]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [8]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [18]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [19]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [23]
GLR2007 DM7DWLY Glioblastoma of brain 2A00.00 Phase 1/2 [24]
FCN-437 DMQ8VUW Breast cancer 2C60-2C65 Phase 1/2 [25]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [26]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [28]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [29]
Methotrexate DM2TEOL Anterior urethra cancer Approved [30]
Folic Acid DMEMBJC Colorectal carcinoma Approved [31]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [30]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [30]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [32]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [30]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [33]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [35]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [36]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [37]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [38]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [39]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [40]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [41]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [42]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [36]
Verapamil DMA7PEW Angina pectoris BA40 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [44]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [45]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [46]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [47]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [48]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [49]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [41]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [50]
Verapamil DMA7PEW Angina pectoris BA40 Approved [51]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [44]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [53]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [54]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [39]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [53]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Metronidazole DMTIVEN Abscess Approved [56]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [57]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [58]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [53]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [3]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Inhibitor [3]
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7372).
2 Apremilast FDA Label
3 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
4 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
5 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
6 Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695.
7 Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
10 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
11 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
12 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
13 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
14 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
15 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
16 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
19 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
20 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
21 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
22 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
25 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
26 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
27 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
28 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
29 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
30 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
31 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
32 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
33 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
34 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
36 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
37 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
38 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
39 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
40 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
41 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
42 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
43 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
44 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
45 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
46 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
47 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
48 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
49 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
50 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
51 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
52 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
53 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
54 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
55 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
56 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
57 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
58 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.